

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/80, 5/10, C12P 21/00		A1	(11) International Publication Number: WO 96/00787 (43) International Publication Date: 11 January 1996 (11.01.96)
<p>(21) International Application Number: PCT/US95/07743</p> <p>(22) International Filing Date: 15 June 1995 (15.06.95)</p> <p>(30) Priority Data: 08/269,449 30 June 1994 (30.06.94) US 08/404,678 15 March 1995 (15.03.95) US </p> <p>(71) Applicant: NOVO NORDISK BIOTECH, INC. [US/US]; Suite 105, 1445 Drew Avenue, Davis, CA 95616-4880 (US).</p> <p>(72) Inventors: ROYER, John, C.; 621 Elm Street, El Cerrito, CA 94530 (US). MOYER, Donna, L.; 5219 Cowell Boulevard, Davis, CA 95616 (US). YODER, Wendy; 8503 Pleasant Valley Road, Winters, CA 95694 (US). SHUSTER, Jeffrey, R.; 2619 Regatta Lane, Davis, CA 95616 (US).</p> <p>(74) Agents: ZELSON, Steve, T. et al.; Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY 10174 (US).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </p>	
<p>(54) Title: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC FUSARIUM EXPRESSION SYSTEM AND PROMOTERS AND TERMINATORS FOR USE THEREIN</p> <p>(57) Abstract</p> <p>The invention is related to a non-toxic, non-toxigenic, non-pathogenic recombinant <i>Fusarium</i>, e.g., <i>Fusarium graminearum</i> host cell comprising a nucleic acid sequence encoding a heterologous protein operably linked to a promoter. The invention further relates to a method for the production of recombinant proteins using such <i>Fusarium</i> host cells. The invention also relates to a promoter and terminator sequence which may be used in such cells.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC *FUSARIUM*
EXPRESSION SYSTEM AND PROMOTERS AND TERMINATORS FOR USE
5 THEREIN

1. FIELD OF THE INVENTION

The present invention relates to host cells useful in the production of recombinant proteins. In particular, the invention relates to non-toxic, non-toxigenic, and non-pathogenic fungal host cells of *Fusarium* which can be used in the high-level expression of recombinant proteins, especially enzymes. The invention further relates to promoter and terminator sequences which may be used in such a system.

2. BACKGROUND OF THE INVENTION

15 The use of recombinant host cells in the expression of heterologous proteins has in recent years greatly simplified the production of large quantities of commercially valuable proteins, which otherwise are obtainable only by purification from their native sources. Currently, there is a varied selection of expression systems from which to choose for the production of any given protein, including prokaryotic and eukaryotic hosts. The selection of 20 an appropriate expression system will often depend not only on the ability of the host cell to produce adequate yields of the protein in an active state, but also to a large extent may be governed by the intended end use of the protein.

25 Although mammalian and yeast cells have been the most commonly used eukaryotic hosts, filamentous fungi have now begun to be recognized as very useful as host cells for recombinant protein production. Examples of filamentous fungi which are currently used or proposed for use in such processes are *Neurospora crassa*, *Acremonium chrysogenum*, *Tolypocladium geodes*, *Mucor circinelloides* and *Trichoderma reesei*, *Aspergillus nidulans*, *Aspergillus niger* and *Aspergillus oryzae*.

30 Certain species of the genus *Fusarium* have been used as model systems for the studies of plant pathogenicity and gene regulation such as *Fusarium oxysporum* (Diolez et al., 1993, Gene 131:61-67; Langin et al., 1990, Curr. Genet. 17:313-319; Malardier et al., 1989, Gene 78:147-156 and Kistler and Benny, 1988, Curr. Genet. 13:145-149), *Fusarium solani* (Crowhurst et al., 1992, Curr. Genet. 21:463-469), and *Fusarium culmorum* (Curragh et al., 1992, Mycol. Res. 97:313-317). These *Fusarium* sp. would not be suitable commercially for 35 the production of heterologous proteins because of their undesirable characteristics such as being plant pathogens or because they produce unsafe levels of mycotoxin. Dickman and Leslie (1992, Mol. Gen. Genet. 235:458-462) discloses the transformation of *Gibberella zaeae* with a plasmid containing *nit-2* of *Neurospora crassa*. The strain of *Gibberella zaeae* disclosed in Dickman and Leslie is a plant pathogen and produces zearalenone, an estrogenic mycotoxin.

Sanchez-Fernandez et al. (1991, Mol. Gen. Genet. 225:231-233) discloses the transformation of *Gibberella fujikoroi* carrying a *niaD* mutation with a plasmid containing the *Aspergillus niger* *niaD* gene.

An ideal expression system is one which is substantially free of protease and
5 mycotoxin production, also substantially free of large amounts of other endogenously made secreted proteins, and which is capable of higher levels of expression than known host cells. The present invention now provides new *Fusarium* expression systems which fulfill these requirements.

10 3. SUMMARY OF THE INVENTION

The present invention provides a recombinant non-toxic, non-toxigenic, and non-pathogenic *Fusarium* host cell comprising a nucleic acid sequence encoding a heterologous protein operably linked to a promoter. As defined herein, "non-toxic" means that the host cell does not act as a poison to plants or animals. For example, a *Fusarium* host cell would be
15 considered non-toxic if about 14 days after injecting about 5 mice with a dose of about 20 ml of (1:1 diluted) 3 day old *Fusarium* culture medium/kg body wt./mouse, none of the mice died as a result of *Fusarium* treatment. As defined herein, "non-toxigenic" means that the host cells are essentially free of mycotoxin as determined by standard analytical methods such as HPLC analysis. For example, an amount of *Fusarium* grown on 2 x 9 cm petri dishes containing
20 solid nutrient medium may be extracted with organic solvents and 0.5% of the extract may be injected into an HPLC for analysis. The absence of known mycotoxins would be inferred by the absence of detectable HPLC peaks at positions known for mycotoxin standards. As defined herein, "non-pathogenic" means that the host cells do not cause significant disease in healthy plants or healthy animals. For example, a *Fusarium* sp. that is pathogenic to plants can
25 show a fungal invasion of the xylem tissue of the plant and result in the disease state characterized by typical wilt symptoms. As defined herein, a "heterologous protein" is a protein which is not native to the host cell, or a native protein in which modifications have been made to alter the native sequence or a native protein whose expression is quantitatively altered as a result of a manipulation of a native regulatory sequence required for the expression of the
30 native protein, such as a promoter, a ribosome binding site, etc. or other manipulation of the host cell by recombinant DNA techniques. The nucleic acid sequence is operably linked to a suitable promoter sequence, which is capable of directing transcription of the nucleic acid sequence in the chosen host cell.

The invention also relates to a method for production of recombinant proteins,
35 the method comprising culturing a host cell of one of the aforementioned species, which host cell contains a nucleic acid sequence encoding a heterologous protein, under conditions conducive to expression of the protein, and recovering the protein from the culture. In a

preferred embodiment, the protein is a fungal protein, most preferably a fungal enzyme. Using the method of the present invention, at least about 0.5 g heterologous protein/l host cell is produced.

The host cell of the present invention secretes unexpectedly only low amounts of protease as determined by the casein clearing assay described in Section 6.1, *infra*; specifically only small or no zones of hydrolysis are detected. The host cells and methods of the present invention are unexpectedly more efficient in the recombinant production of certain fungal enzymes than are other known fungal species, such as *Aspergillus niger* *Aspergillus oryzae*, or *Fusarium oxysporum*.

The invention further relates to a promoter sequence derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same promoter activity as said sequence. The sequence of the promoter is shown in SEQ ID NO:5.

Additionally, the invention relates to a terminator sequence derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same terminator activity as said sequence. The sequence of the terminator is shown in SEQ ID NO:6.

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows an SDS gel of secreted proteins in *Fusarium graminearum* (lane 1); *Aspergillus niger* (lane 2); and *Aspergillus oryzae* (lane 3). Lane 4 shows molecular weight markers.

Figure 2 shows the results of a protease assay on the following samples: *Aspergillus oryzae* (well 1); *Aspergillus niger* (well 2); *Fusarium graminearum* (well 3); empty well controls (wells 4-6).

Figure 3 shows the construction of plasmid pJRoy6.

Figure 4 shows SDS-PAGE analysis of the secretion of a trypsin-like protease (SP387) in a transformant of *F. graminearum* 20334. Lane 1: molecular size markers; lane 2: blank; lane 3: purified trypsin-like protease protein standard; lane 4: blank; lane 5: *F. graminearum* strain 20334 untransformed; lane 6: blank; lane 7: *F. graminearum* strain 20334 transformed with plasmid pJRoy6; lane 8: blank; lane 9: molecular size markers.

Figure 5 shows a restriction map of pJRoy20.

Figure 6 shows a restriction map of pDM151.

Figure 7 shows a restriction map of pDM155.

Figures 8A and 8B show the level of expression of Carezyme® in *Fusarium graminearum* when DSM 151-4 is fermented in *Fusarium graminearum* from 20-160 hrs. Figure 8A shows the results of an assay for Carezyme®. Figure 8B shows SDS-PAGE

analysis of the production of Carezyme® in said *Fusarium graminearum*. Lane 1:molecular size markers; lane 2:20 hrs.; lane 3:50 hrs.; lane 4:70 hrs.; lane 5:90 hrs.; lane 6:120 hrs.; lane 7:140 hrs.; lane 8:160 hrs.

- Figures 9A and 9B show the level of expression of Lipolase® when DSM 155-5. 10 is fermented in *Fusarium graminearum* from 20-160 hrs. Figure 9A shows the results of an assay for Lipolase®. Figure 9B shows SDS-PAGE analysis of the production of Lipolase® in said *Fusarium graminearum*. Lane 1:molecular size markers; lane 2:20 hrs.; lane 3:50 hrs.; lane 4:60 hrs.; lane 5:90 hrs.; lane 6:120 hrs.; lane 7:140 hrs.; lane 8:160 hrs.

Figure 10 shows a restriction map of pCaHj418.

10 Figure 11 shows a restriction map of pDM148.

Figure 12 shows a restriction map of pDM149.

Figure 13 shows a restriction map of pMHan37.

Figure 14 shows a restriction map of pDM154.

15 5. DETAILED DESCRIPTION OF THE INVENTION

Fusarium are characterized by mycelium extensive and cotton-like in culture, often with some tinge of pink, purple or yellow in the mycelium on solid medium.

Conidiophores are variable slender and simple, or stout, short, branched irregularly or bearing a whorl of phialides, single or grouped into sporodochia. Conidia are principally of two kinds, often held in small moist heads: macroconidia several-celled, slightly curved or bent at the pointed ends, typically canoe-shaped and microconidia which are one celled, ovoid or oblong, borne singly or in chains. Some conidia are intermediate, 2 or 3 celled, oblong or slightly curved.

In a specific embodiment, the host cells of the present invention are of the species *Fusarium graminearum* which is characterized by the following features. Conidia: Microconidia are absent. Macroconidia are distinctly septate, thick walled, straight to moderately sickle-shaped, unequally curved with the ventral surface almost straight and a smoothly arched dorsal surface. The basal cell is distinctly foot-shaped. The apical cell is cone-shaped or constricted as a snout. Conidiophores: unbranched and branched monophialides. Chlamydospores: are generally very slow to form in culture: when they do occur, they most often form in the macroconidia but may also form in the mycelium. Colony morphology: on PDA, growth is rapid with dense aerial mycelium that may almost fill the tube and is frequently yellow to tan with the margins white to carmine red. Red-brown to orange sporodochia, if present, are sparse, often appearing only when the cultures are more than 30 days old. The undersurface is usually carmine red. This fungus produces the most cylindrical (dorsal and ventral surfaces parallel) macroconidia of any species of the section *Discolor*.

In a most specific embodiment, the *Fusarium graminearum* is *Fusarium*

graminearum Schwabe IMI 145425, deposited with the American Type Culture Collection and assigned the number ATCC 20334 (U.S. Patent No. 4,041,189), as well as derivatives and mutants which are similarly non-toxic, non-toxigenic, and non-pathogenic, e.g. those taught in U.S. Patent No. 4,041,189.

5 It will be understood that throughout the specification and claims the use of the term "*Fusarium graminearum*" refers not only to organisms encompassed in this species, but also includes those species which have previously been or currently are designated as other species in alternate classification schemes, but which possess the same morphological and cultural characteristics defined above, and may be synonymous to *F. graminearum*. These
10 include but are not limited to *Fusarium roseum*, *F. roseum* var. *graminearum*, *Gibberella zae*, or *Gibberella roseum*, *Gibberella roseum* f. sp. *cerealis*.

The skilled artisan will also recognize that the successful transformation of the host species described herein is not limited to the use of the vectors, promoters, and selection markers specifically exemplified. Generally speaking, those techniques which are useful in
15 transformation of *F. oxysporum*, *F. solani* and *F. culmorum* are also useful with the host cells of the present invention. For example, although the *amdS* selection marker is preferred, other useful selection markers include the *argB* (*A. nidulans* or *A. niger*), *trpC* (*A. niger* or *A. nidulans*), *pyrG* (*A. niger*, *A. oryzae* or *A. nidulans*), *niaD* (*A. nidulans*, *A. niger*, or *F. oxysporum*), and *hygB* (*E. coli*) markers. The promoter may be any DNA sequence that
20 shows strong transcriptional activity in these species, and may be derived from genes encoding both extracellular and intracellular proteins, such as amylases, glucoamylases, proteases, lipases, cellulases and glycolytic enzymes. Examples of such promoters include but are not limited to *A. nidulans* *amdS* promoter or promoters from genes for glycolytic enzymes, e.g., TPI, ADH, GAPDH, and PGK. The promoter may also be a homologous promoter, i.e., the
25 promoter for a gene native to the host strain being used. The promoter sequence may also be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the promoter sequence with the gene of choice or with a selected signal peptide or preregion.

The promoter sequence may be derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same promoter
30 activity as said sequence. The sequence of the promoter is shown in SEQ ID NO:5. The invention further encompasses nucleic acid sequences which hybridize to the promoter sequence shown in SEQ ID NO:5 under the following conditions: presoaking in 5X SSC and prehybridizing for 1 hr. at about 40°C in a solution of 20% formamide, 5X Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 ug denatured sonicated calf thymus DNA,
35 followed by hybridization in the same solution supplemented with 100 uM ATP for 18 hrs. at about 40°C, followed by a wash in 0.4X SSC at a temperature of about 45°C, or which have at least about 90% homology and preferably about 95% homology to SEQ ID NO:5, but which

have substantially the same promoter activity as said sequence. In another embodiment, the promoter may be a sequence comprising a large number of binding sites of AreA, a positive regulator of genes expressed during nitrogen limitation; these sites are referred to as *nit-2* in *Neurospora crassa* (Fu and Marzlus, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:5331-5335).

- 5 The promoter sequence may be modified by the addition or substitution of such AreA sites.

Terminators and polyadenylation sequences may also be derived from the same sources as the promoters. In a specific embodiment, the terminator sequence may be derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same terminator activity as said sequence. The sequence of the 10 terminator is shown in SEQ ID NO:6. The invention further encompasses nucleic acid sequences which hybridize to the terminator sequence shown in SEQ ID NO:6 under the following conditions: presoaking in 5X SSC and prehybridizing for 1 hr. at about 40°C in a solution of 20% formamide, 5X Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 ug denatured sonicated calf thymus DNA, followed by hybridization in the same solution 15 supplemented with 100 uM ATP for 18 hrs. at about 40°C, followed by a wash in 0.4X SSC at a temperature of about 45°C, or which have at least about 90% homology and preferably about 95% homology to SEQ ID NO:5, but which have substantially the same terminator activity as said sequence.

Enhancer sequences may also be inserted into the construct.

- 20 To avoid the necessity of disrupting the cell to obtain the expressed product, and to minimize the amount of possible degradation of the expressed product within the cell, it is preferred that the product be secreted outside the cell. To this end, in a preferred embodiment, the gene of interest is linked to a preregion such as a signal or leader peptide which can direct the expressed product into the cell's secretory pathway. The preregion may 25 be derived from genes for any secreted protein from any organism, or may be the native preregion. Among useful available sources for such a preregion are a glucoamylase or an amylase gene from an *Aspergillus* species, an amylase gene from a *Bacillus* species, a lipase or proteinase gene from *Rhizomucor miehei*, the gene for the α -factor from *Saccharomyces cerevisiae*, or the calf prochymosin gene. The preregion may be derived from the gene for *A. oryzae* TAKA amylase, *A. niger* neutral α -amylase, *A. niger* acid stable α -amylase, *B. licheniformis* α -amylase, the maltogenic amylase from *Bacillus* NCIB 11837, *B. stearothermophilus* α -amylase, or *B. licheniformis* subtilisin. An effective signal sequence is the *A. oryzae* TAKA amylase signal, the *Rhizomucor miehei* aspartic proteinase signal and the *Rhizomucor miehei* lipase signal. As an alternative, the preregion native to the gene being 30 expressed may also be used, e.g., in SEQ ID NO:4 between amino acids -24 and -5.

The gene for the desired product functionally linked to promoter and terminator sequences may be incorporated in a vector containing the selection marker or may be placed on a separate vector or plasmid capable of being integrated into the genome of the host strain.

Alternatively, the vectors used may be capable of replicating as linear or circular

- 5 extrachromosomal elements in the host cell. These types of vectors include for example, plasmids and minichromosomes. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be integrated into the genome. Vectors or plasmids may be linear or closed circular molecules.

- 10 The host cell may be transformed with the nucleic acid encoding the heterologous protein using procedures known in the art such as transformation and electroporation (see, for example, Fincham, 1989, *Microbial Rev.* 53:148-170).

- 15 The recombinant host cell of the present invention may be cultured using procedures known in the art. Briefly, the host cells are cultured on standard growth medium such as those containing a combination of inorganic salts, vitamins, a suitable organic carbon source such as glucose or starch, any of a variety of complex nutrients sources (yeast extract, hydrolyzed casein, soya bean meal, etc.). One example is FP-1 medium (5% soya bean meal, 5% glucose, 2% K₂HPO₄, 0.2% CaCl₂, 0.2% MgSO₄·7H₂O and 0.1% pluronic acid (BASF)). The fermentation is carried out at a pH of about 4.5-8.0, and at a temperature of about 20-37°C for about 2-7 days.

- 20 The present host cell species can be used to express any prokaryotic or eukaryotic heterologous protein of interest, and is preferably used to express eukaryotic proteins. Of particular interest for these species is their use in expression of heterologous proteins, especially fungal enzymes. The novel expression systems can be used to express enzymes such as catalase, laccase, phenoloxidase, oxidase, oxidoreductases, cellulase, 25 xylanase, peroxidase, lipase, hydrolase, esterase, cutinase, protease and other proteolytic enzymes, aminopeptidase, carboxypeptidase, phytase, lyase, pectinase and other pectinolytic enzymes, amylase, glucoamylase, α-galactosidase, β-galactosidase, α-glucosidase, β-glucosidase, mannosidase, isomerase, invertase, transferase, ribonuclease, chitinase, mutanase and deoxyribonuclease.

- 30 In a specific embodiment, the enzyme is an alkaline protease, e.g., a *Fusarium oxysporum* pre-pro-trypsin gene. In a most specific embodiment, the genomic sequence is shown in SEQ ID NO:3 and the protein sequence is shown in SEQ ID NO:4.

- 35 In another specific embodiment, the enzyme is an alkaline endoglucanase, which is immunologically reactive with an antibody raised against a highly purified ~43 kD endoglucanase derived from *Hemicola insolens*, DSM 1800, or which is a derivative of the ~43 kD endoglucanase exhibiting cellulase activity (cf. WO 91/17243). The endoglucanase,

hereinafter referred to as "Carezyme®" may be encoded by a gene shown in SEQ ID NO:7 and may have a protein sequence shown in SEQ ID NO:8. The enzyme may also be a Carezyme® variant.

In yet another specific embodiment, the enzyme is a 1,3-specific lipase, 5 hereinafter referred to as Lipolase®. The enzyme may be encoded by the DNA sequence shown in SEQ ID NO:9 and may have an amino acid sequence shown in SEQ ID NO:10. The enzyme may also be a Lipolase® variant, e.g., D96L, E210K, E210L (see WO 92/05249).

It will be understood by those skilled in the art that the term "fungal enzymes" includes not only native fungal enzymes, but also those fungal enzymes which have been 10 modified by amino acid substitutions, deletions, additions, or other modifications which may be made to enhance activity, thermostability, pH tolerance and the like. The present host cell species can also be used to express heterologous proteins of pharmaceutical interest such as hormones, growth factors, receptors, and the like.

The present invention will be further illustrated by the following non-limiting 15 examples.

6. EXAMPLES

6.1. *Fusarium graminearum* 20334 Secretes Only a Low Level of 20 Protein

Conidial spore suspensions of *Fusarium graminearum* strain 20334, an *A. oryzae*, and *A. niger* are inoculated into 25 ml of YPD medium (1% yeast extract (Difco), 2% bactopeptone (Difco), 2% glucose) in a 125 ml shake flask and incubated at 30°C at 300 rpm for 5 days. Supernatant broths from the cultures are harvested by centrifugation. A total of 25 10 µl of each sample are mixed with 10 µl 0.1 M dithiothreitol (Sigma) and 10 µl of loading buffer (40 mM Tris base, 6% sodium dodecyl sulfate, 2.5 mM EDTA, 15% glycerol, 2 mg/ml bromocresol purple). The samples are boiled for 5 minutes and run on a 4-12% polyacrylamide gel (Novex). The proteins are visualized by staining with Coomassie Blue. The results (Figure 1) show that *Fusarium graminearum* strain 20334 produces very little secreted protein.

30 6.2. *Fusarium graminearum* 20334 Secretes Only a Low Level of Proteases

A total of 40 µl of culture broths from *Fusarium graminearum* strain 20334, *A. oryzae*, and *A. niger* (see Section 6.1., *supra*) are each pipetted into wells that are cut into a 35 casein agar plate (2% non-fat dry milk (Lucerne), 50 mM Tris-HCl pH=7.5, 1% noble agar (Difco)). The plates are incubated at 37°C for 5 hours and the zones of protein hydrolysis are observed. The results (Figure 2) show that *Fusarium graminearum* strain 20334 broth contains

very little proteolytic activity.

6.3. Cloning of *Fusarium oxysporum* Genomic Prepro-trypsin Gene

A genomic DNA library in lambda phage is prepared from the *F. oxysporum* genomic DNA using methods such as those described found in Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY. A total of 50 µg genomic DNA are digested in a volume of 200 µl containing 10 mM Tris (pH=7.5), 50 mM NaCl, 7 mM MgCl₂, 7 mM 2-mercaptoethanol, and 4 units restriction enzyme Sau3A for one minute at 37°C. Partially digested DNA of molecular size 10-20 kb is isolated by agarose gel electrophoresis, followed by electroelution into dialysis membrane and concentration using an Elutip-D column (Schleicher and Schuell). One µg of lambda arms of phage of EMBL4 that had been cut with restriction enzyme BamH1 and treated with phosphatase (Clonetech) is ligated with 300-400 µg Sau3A cut genomic DNA in a volume of 25 µl under standard conditions (see Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY). Lambda phage are prepared from this ligation mix using a commercially available kit (Gigapack Gold II, Stratagene) following the manufacturers directions.

The plating of ca. 15,000 recombinant lambda phage and the production of filter lifts (to Hybond N⁺ filters, Amersham) are performed using standard methods (Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY). The filters are processed for hybridization with a Genius Kit for nonradioactive nucleic acids detection (Boehringer Mannheim) using standard methods (Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY). The DNA used as a probe is a 0.75 kb digoxigenin (DIG) labeled PCR fragment of the entire coding region of the *F. oxysporum* trypsin-like protease (hereinafter referred to as SP387) gene present in plasmid pSX233, which has been deposited with the NRRL under the accession number of NRRL B-21241. The primers for the PCR reaction are 5'-tgccggatccATGGTCAAGTTCGCTTCCGTC (forward primer; SEQ ID NO:1) and 5'-gacctcgagTTAACGCATAGGTGTCAATGAA (reverse primer; SEQ ID NO:2). In both primers, the lower case characters represent linker sequences and the upper case characters correspond to the coding region of the SP387 gene. To perform the PCR, 25 ng of a 907 bp BarnH1/Xba1 DNA fragment containing the SP387 gene from plasmid pSX233 are mixed with 68 pmoles of each forward and reverse primer.

The mixture of the DNA fragment and primers is made up to an 80 µl volume in 1X Taq Buffer/1X DIG labelling Mix/5 units Taq (Boehringer Mannheim). The reaction conditions are 95°C, 3 minutes, then 35 cycles of [95°C 30 seconds, 50°C 1 minute, 72°C 1 minute]. The DNA sequence derived by PCR from the *F. oxysporum* trypsin-like protease is shown in SEQ ID NO:3. The phage plaques are screened with the DIG labeled probe using a

modification (Engler and Blum, 1993, Anal. Biochem. 210:235-244) of the Genius kit (Boehringer Mannheim). Positive clones are isolated and purified by a second round of plating and hybridization. Recombinant lambda phage containing the *F. oxysporum* trypsin-like protease gene are prepared and DNA is isolated from the phage using a Quiagen lambda midi preparation kit (Quiagen).

6.4. Construction of Expression Plasmid pJRoy6

Restriction mapping, Southern blotting, and hybridization techniques (Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY) are used to identify a 5.5 kb PstI restriction enzyme fragment from one of the recombinant phage that contains the *F. oxysporum* trypsin-like protease coding gene and flanking DNA sequences. This 5.5 kb PstI fragment is subcloned into PstI digested pUC118 and the plasmid is designated pJRoy4 (see Figure 3). Plasmid pJRoy4 is digested with restriction enzyme EcoR1 and a 3.5 kb EcoR1 fragment containing the SP387 gene and the 43 bp EcoR1/PstI region of the pUC118 polylinker is isolated and subcloned into the vector pToC90 to create plasmid pJRoy6 (Figure 3).

6.5. Construction of SP387 Expression Cassette

An expression cassette (pJRoy20) containing the SP387 promoter and terminator joined by a BamH1 site in pUC118 is constructed. An *E. coli* strain containing pJRoy20 has been deposited with the NRRL. The promoter fragment is generated by digesting the SP387 vector pJRoy6 with EcoR1 (which cuts at -1200) and with Nco1 (which cuts at the translational start site, see Figure 5). The terminator sequence (bp 2056-3107 in Figure 5) is generated by PCR amplification using the following oligonucleotides:

25

FORWARD

5'gcacaccatggcgctggatccATACCTTGTGGAAGCGTCG3' (SEQ ID NO:11)

REVERSE

30

5'atcggagcatgcggtaccgttaaacgaattcAGGTAAACAAGATATAATTCTG 3' (SEQ ID NO:12)

Letters in large case are complementary to SP387 terminator DNA, while lower case letters are tails containing engineered restriction sites.

35

After digestion with Nco1 and Sph1, the resulting amplification product containing the terminator flanked by Nco1 and BamH1 sites on the 5' end, and flanked by EcoR1, Pme1, Kpn1 and Sph1 sites on the 3' end is isolated. A 3-way ligation between the

promoter fragment, the terminator fragment and Kpn1/Sph1 cut pUC118 is performed to generate pJRoy20 (see Figure 5).

6.6. Carezyme® Constructs

The EcoRV site at -15 in the SP387 promoter, and the NcoI site present at +243 in the Carezyme® coding region are utilized to create an exact fusion between the SP387 promoter and the Carezyme® gene. A PCR fragment containing -18 to -1 of the SP387 promoter directly followed by -1 to +294 of the Carezyme® gene is generated from the Carezyme® vector pCaHj418 (see Figure 10) using the following primers:

10

FORWARD

EcoRV

5'ctcttggatatctatcttcaccATGCGTTCCCTCCCCCTCCT3' (SEQ ID NO:13)

15

REVERSE

5'CAATAGAGGTGGCAGCAAAA 3' (SEQ ID NO:14)

Lower case letters in the forward primer ar bp -24 to -1 of the SP387 promoter, while upper case letters are bp 1 to 20 of Carezyme®.

20

The PCR conditions used are: 95°C, 5 min. followed by 30 cycles of [95°C, 30sec., 50°C, 1 min., 72°C, 1 min.]. The resulting 0.32 kb fragment is cloned into vector pCRII using Invitrogen's TA cloning kit resulting in pDM148 (see Figure 11). The 0.26 kb EcoRV/NcoI fragment is isolated from pDM148 and ligated to the 0.69 kb NcoI/BglII fragment from pCaHj418 and cloned into EcoRV/BamHI digested pJRoy20 to create pDM149 (see Figure 12). The 3.2 kb EcoRI Carezyme® expression cassette (SP387 promoter/Carezyme®/SP387 terminator) is isolated from pDM149 and cloned into the EcoRI site of pToC90 to create pDM151 (see Figure 6). Expression construct pDM151 contains both the expression cassette and the *amdS* selectable marker. An *E. coli* strain containing pDM151 has been deposited with the NRRL.

25

30

6.7. Lipolase® Constructs

The EcoRV site at -15 in the SP387 promoter, and the SacI site at +6 in the Lipolase® coding region are utilized to create an exact fusion between the SP387 promoter and the Lipolase® gene. An adapter containing the final 15 bp of the SP387 promoter followed by the first 6 bp of the Lipolase® coding region is constructed and is shown below.

EcoRV	SacI
atctatctttaccATGAGGAGCT	(SEQ ID NO:15)
tagatagagaagtggTACTCC	(SEQ ID NO:16)

- 5 A 0.9 kb SacI/BamHI fragment of the Lipolase® cDNA gene is isolated from the *A.oryzae* expression construct pMHan37 (see Figure 13). The EcoRV/SacI adapter and SacI/BamHI Lipolase® fragment are ligated and cloned into EcoRV/BamHI digested pJRoy20 to create plasmid pDM154 (see Figure 14). The 3.2 kb KpnI Lipolase® expression cassette (SP387 promoter/Lipolase®/SP387 terminator) is isolated from pDM154 and cloned into the KpnI site of pToC90 to create plasmid pDM155 (see Figure 7). Expression construct pDM155 contains both the Lipolase® expression cassette and the *andS* selectable marker. An *E. coli* strain containing pDM151 has been deposited with the NRRL.
- 10

6.8. Transformation of *F. graminearum*

- 15 *Fusarium graminearum* strain ATCC 20334 cultures are grown on 100 x 15 mm petri plates of Vogels medium (Vogel, 1964, Am. Nature 98:435-446) plus 1.5% glucose and 1.5% agar for 3 weeks at 25°C. Conidia (approximately 10⁸ per plate) are dislodged in 10 ml of sterile water using a transfer loop and purified by filtration through 4 layers of cheesecloth and finally through one layer of miracloth. Conidial suspensions are concentrated by centrifugation. Fifty ml of YPG (1% yeast extract (Difco) 2% bactopeptone (Difco), 2% glucose) are inoculated with 10⁸ conidia, and incubated for 14 h at 20°C, 150 rpm. Resulting hyphae are trapped on a sterile 0.4 µm filter and washed successively with sterile distilled water and 1.0 M MgSO₄. The hyphae are resuspended in 10 ml of Novozym® 234 (Novo Nordisk) solution (2-10 mg/ml in 1.0 M MgSO₄) and digested for 15-30 min at 34°C
- 20
- 25 with agitation at 80 rpm. Undigested hyphal material is removed from the resulting protoplast suspension by successive filtration through 4 layers of cheesecloth and through miracloth. Twenty ml of 1M sorbitol are passed through the cheesecloth and miracloth and combined with the protoplast solution. After mixing, protoplasts (approximately 5 x 10⁸) are pelleted by centrifugation and washed successively by resuspension and centrifugation in 20 ml of 1M
- 30 sorbitol and in 20 ml of STC (0.8 m sorbitol, 50 mM Tris-HCl pH=8.0, 50 mM CaCl₂). The washed protoplasts are resuspended in 4 parts STC and 1 part SPTC (0.8M sorbitol, 40% polyethylene glycol 4000 (BDH), 50 mM Tris-HCl pH=8.0, 50 mM CaCl₂) at a concentration of 1-2 x 10⁸/ml. One hundred µl of protoplast suspension are added to 5 µg pJRoy6 and 5 µl heparin (5 mg/ml in STC) in polypropylene tubes (17 x 100 mm) and
- 35 incubated on ice for 30 min. One ml of SPTC is mixed gently into the protoplast suspension and incubation is continued at room temperature for 20 min. Protoplasts are plated on a

selective medium consisting of Cove salts (Cove, D.J., 1966, Biochem. Biophys. Acta 113:51-56) plus 10 mM acetamide, 15 mM CsCl₂, 2.5% noble agar (Difco) and 1.0 M sucrose using an overlay of the same medium with 0.6 M sucrose and 1.0% low melting agarose (Sigma). Plates are incubated at 25°C and transformants appeared in 6-21 days.

5

6.9. Expression of trypsin-like protease in *Fusarium graminearum*

Transformants are transferred to plates of COVE2 medium (same as COVE medium above without the cesium chloride and replacing the 1.0 M sucrose with a concentration of 30 g/l) and grown for 3 or more days at 25°C. Twenty five ml aliquots of FP-1 medium (5% soya bean meal, 5% glucose 2% K₂HPO₄, 0.2% CaCl₂, 0.2% MgSO₄.7H₂O and 0.1% pluronic acid (BASF)) in 150 ml flasks are inoculated with approximately 1 cm agar plugs from COVE2 plate cultures and incubated for 6 days at 30°C with agitation (150 rpm). Supernatant broth samples are recovered after centrifugation and subjected to SDS-PAGE analysis as follows. Thirty µl of each broth is mixed with 10 µl SDS-PAGE sample buffer (1 ml 0.5 M Tris pH=6.8, 0.8 ml glycerol, 1.6 ml 10% SDS, 0.4 ml 0.8 M dithiothreitol, 0.2 ml 1% bromophenol blue), 2 µl of 2% PMSF (Sigma) in isopropanol, and 2 µl glycerol. The samples are placed in a boiling water bath for 4 minutes and 40 µl of each are run on a 10-27% polyacrylamide gel (Novex). The gels are stained and destained with Coomassie dye using standard methods. The expression level of the trypsin-like protease has been determined to be ≥ 0.5 g/l.

6.10. Enzyme assays

6.10.1. Carezyme®

25

Buffer: Sodium phosphate (50 mM, pH 7.0)

Substrate: AZCL-HE cellulose (Megazyme) at 2 mg/ml buffer

30

Enzyme std: 100 mg of Carezyme® standard (10,070 ECU/g) is dissolved in 1 ml buffer and stored at -20°C. This stock is diluted 1:100 in buffer immediately prior to use in enzyme assays. The assay range is 0.5 - 5.0 ECU/ml. A conversion factor of 650,000 ECU/g Carezyme® is used.

35

Substrate solution (990 µl) is added to sample wells of a 24-well microtiter plate. Ten µl of Carezyme® sample (diluted in buffer to produce activity of between 0.5 and 10 ECU/ml.) are added to the substrate. Reactions are incubated for 30 minutes at 45°C with

supernatant are transferred to a 96-well microtiter plate and the absorbance at 650 nm is measured.

6.10.2. Lipolase® Assay

5

Buffer: 0.1M MOPS, pH 7.5 containing 4 mM CaCl₂

Substrate: 10 mL p-nitrophenyl butyrate (pNB)
in 1 ml DMSO;

10

Add 4 ml buffer to substrate in DMSO

*Stock concentration = 11.5 mM in 20% DMSO

Enzyme std:Lipolase® (23,100 LU/g) is dissolved at
1000LU/ml in 50% glycerol and stored at -20°C.

15

This stock is diluted 1:100 in buffer
immediately prior to assay. The assay range is
0.125 to 3.0 LU/ml.

100 µl pNB stock solution is added to 100 µl of appropriately diluted enzyme
20 sample. Activity (mOD/min) is measured at 405 nm for 5 min at 25°C.

6.10.3. SP387 Assay

L-BAPNA substrate is prepared by dilution of a 0.2 M stock solution of L-BAPNA (Sigma B3133) in dimethyl sulfoxide (stored frozen) to 0.004 M in buffer (0.01 M dimethylglutaric acid (Sigma), 0.2 M boric acid and 0.002 M calcium chloride, adjusted to pH 6.5 with NaOH) just prior to use. One µl of culture was centrifuged (145000 x g, 10 min). A 100 µl aliquot of diluted culture broth is added to 100 µl substrate in a 96 well microtiter plate. Absorption change at 405 nm is assayed at 30 second intervals for 5 min. at 25°C using an ELISA reader. Results are calculated relative to a purified SP387 standard.

30

6.11. Expression of Carezyme®

Twenty-three transformants of pDM151 are purified, cultured in shake flasks on soy/glucose medium and assayed for Carezyme® activity after 9 days (Table 1-see below). Four transformants express Carezyme® at a level of approximately 50-100 mg/L.

35 Transformant pDM151-4 is cultured in small scale fermentors using the conditions developed for SP387 production (see Section 6.9). Approximately 6.0 g/L of Carezyme® is evident after 7 days (Figure 8A). Carezyme® comprised greater than 90% of secreted proteins based on

7 days (Figure 8A). Carezyme® comprised greater than 90% of secreted proteins based on SDS gel electrophoresis (Figure 8B).

TABLE I

5

Transformant #	ECU/ml	mg/L
pDM 151.3 - 4	58.2	90
pDM 151.3 - 5	0	0
pDM 151.3 - 6	0	0
pDM 151.3 - 10	0	0
pDM 151.3 - 11	2.46	4
pDM 151.3 - 12	0	0
pDM 151.3 - 13	12.2	19
pDM 151.3 - 14	47.3	73
pDM 151.3 - 15	22.7	35
pDM 151.3 - 16	0	0
pDM 151.3 - 17	0	0
pDM 151.3 - 18	0	0
pDM 151.3 - 19	0	0
pDM 151.3 - 21	0	0
pDM 151.3 - 22	43.7	67
pDM 151.3 - 23	1.25	2
pDM 151.3 - 24	17.8	27
pDM 151.3 - 25	38	58
pDM 151.3 - 26	0	0
pDM 151.3 - 27	10.5	16
pDM 151.3 - 28	49.3	76
pDM 151.3 - 29	19.8	30
pDM 151.3 - 30	22.7	35

10

15

20

25

6.12. Expression of Lipolase®

Fifteen transformants of pDM155 are purified, cultured in shake flasks in soy/glucose medium and assayed for Lipolase® activity after 9 days (Table 2-see next page).

30

TABLE II

Transformant #	LU/ml	mg/ml
pDM 155 - 1	669	167
pDM 155 - 2	45.2	11
pDM 155 - 3	180	45
pDM 155 - 4	0	0
pDM 155 - 5	55.4	14
pDM 155 - 6	116	29
pDM 155 - 7	704	176
pDM 155 - 8	214	54
pDM 155 - 9	17.1	4
pDM 155 - 10	712	178
pDM 155 - 11	511	128
pDM 155 - 12	0	0
pDM 155 - 13	0	0
pDM 155 - 14	0	0
pDM 155 - 15	153	38
pDM 155 - 16	0	0
pDM 155 - 17	0	0
pDM 155 - 18	0	0
pDM 155 - 19	129	32
pDM 155 - 20	378	95
pDM 155 - 21	216	54

Four transformants expressed Lipolase® at a level of approximately 100-200 mg/l (based on the pNB assay). Transformant pDM155-10 is cultured in small scale fermentors using the conditions developed for SP387 production (see Section 6.9). Approximately 2.0 g/l of Lipolase is evident after 7 days (Figure 8A). Lipolase® comprised greater than 90% of secreted proteins based on SDS gel electrophoresis (Figure 8B).

7. DEPOSIT OF MICROORGANISMS

The following biological materials have been deposited in the Agricultural Research Service Patent Culture Collection (NRRL), Northern Regional Research Center, 1815 University Street, Peoria, Illinois, 61604, USA.

<u>Strain</u>	<u>Accession No.</u>	<u>Deposit Date</u>
<i>E. coli</i> containing	NRRL B-21285	6/20/94
35 pJRoy6		
<i>E. coli</i> containing	NRRL B-21418	3/10/95

E. coli containing NRRL B-21419 3/10/95
pDM151

5 *E. coli* containing NRRL B-21420 3/10/95
pDM155

The strains have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122 and under conditions of the Budapest Treaty. The deposit represents a biologically pure culture of each deposited strain. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

25

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Novo Nordisk Biotech, Inc.
- (B) STREET: 1445 Drew Avenue, Ste. 105
- (C) CITY: Davis
- (D) STATE: California
- (E) COUNTRY: US
- (F) ZIP: 95616-4880
- (G) TELEPHONE: (916) 757-8100
- (H) TELEFAX: (916) 758-0317

(ii) TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
FUSARIUM EXPRESSION SYSTEM AND PROMOTERS AND TERMINATORS FOR USE THEREIN

(iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Novo Nordisk of North America, Inc.
- (B) STREET: 405 Lexington Avenue, 64th Floor
- (C) CITY: New York
- (D) STATE: New York
- (E) COUNTRY: USA
- (F) ZIP: 10174-6401

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: to be assigned
- (B) FILING DATE: 15-June-1995
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/269,449
- (B) FILING DATE: 30-June-1994

(viii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/404,678
- (B) FILING DATE: 15-March-1995

(ix) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Agris Dr., Cheryl H.
- (B) REGISTRATION NUMBER: 34,086
- (C) REFERENCE/DOCKET NUMBER: 4216.204-WO

(x) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 212-867-0123
- (B) TELEFAX: 212-878-9655

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGCAGGATCCA TGGTCAAGTT CGCTTCCGTC

30

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GACCTCGAGT TAAGCATAGG TGTCAATGAA

30

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATCATCAACC ACTCTTCACT CTTCAACTCT CCTCTCTTGG ATATCTATCT CTTCACCATG	60
GTCAAGTTCG CTTCCGTCGT TGCACTTGTG GCTCCCCTGG CTGCTGCCGC TCCTCAGGAG	120
ATCCCCAACAA TTGTTGGTGG CACTTCTGCC AGCGCTGGCG ACTTTCCCTT CATCGTGAGC	180
ATTAGCCGCA ACGGTGGCCC CTGGTGTGGA GGTTCTCTCC TCAACGCCAA CACCGTCTTG	240
ACTGCTGCCA ACTGCGTTTC CGGATAACGCT CAGAGCGGTT TCCAGATTG TGCTGGCAGT	300
CTGTCCTCGCA CTTCTGGTGG TATTACCTCC TCGCTTCCCT CCGTCAGAGT TCACCCCTAGC	360
TACAGCGGAA ACAACAACGA TCTTGCTATT CTGAAGCTCT CTACTTCCAT CCCCTCCGGC	420
GGAAACATCG GCTATGCTCG CCTGGCTGCT TCCGGCTCTG ACCCTGTGCG TGGATTTCT	480
GCCACTGTTG CTGGCTGGGG CGCTACCTCT GAGGGCGGCA GCTCTACTCC CGTCAACCTT	540
CTGAAGGTTA CTGTCCTAT CGTCTCTCGT GCTACCTGCC GAGCTCAGTA CGGCACCTCC	600
GCCATCACCA ACCAGATGTT CTGTGCTGGT GTTTCTTCCG GTGGCAAGGA CTCTGCCAG	660
GGTGACACCG CGGGCCCCAT CGTCGACAGC TCCAACACTC TTATCGGTGC TGTCTTTGG	720
GGTAACGGAT GTGCCCGACC CAAACTACTCT GGTGTCTATG CCAGCGTTGG TGCTCTCCGC	780
TCTTTCATTG ACACCTATGC TTAAATACCT TGTTGGAAGC GTCGAGATGT TCCTTGAATA	840
TTCTCTAGCT TGAGTCTTGG ATACGAAACC TGTTTGAGAA ATAGGTTCA ACGAGTTAAG	900
AAGATATGAG TTGATTTCAAG TTGGATCTTA GTCCCTGGTTG CTCGTAATAG AGCAATCTAG	960
ATAGCCAAA TTGAATATGA AATTGATGA AAATATTC	998

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 248 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..224

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: -24..0
- (D) OTHER INFORMATION: /product= "OTHER"

/note= "Label=pre-propeptide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Val	Lys	Phe	Ala	Ser	Val	Val	Ala	Leu	Val	Ala	Pro	Leu	Ala	Ala
	-20								-15						-10

Ala	Ala	Pro	Gln	Glu	Ile	Pro	Asn	Ile	Val	Gly	Gly	Thr	Ser	Ala	Ser
	-5							1						5	

Ala	Gly	Asp	Phe	Pro	Phe	Ile	Val	Ser	Ile	Ser	Arg	Asn	Gly	Gly	Pro
	10				15						20				

Trp	Cys	Gly	Gly	Ser	Leu	Leu	Asn	Ala	Asn	Thr	Val	Leu	Thr	Ala	Ala
	25				30					35					40

His	Cys	Val	Ser	Gly	Tyr	Ala	Gln	Ser	Gly	Phe	Gln	Ile	Arg	Ala	Gly
		45						50					55		

Ser	Leu	Ser	Arg	Thr	Ser	Gly	Gly	Ile	Thr	Ser	Ser	Leu	Ser	Ser	Val
	60							65				70			

Arg	Val	His	Pro	Ser	Tyr	Ser	Gly	Asn	Asn	Asn	Asp	Leu	Ala	Ile	Leu
	75							80						85	

Lys	Leu	Ser	Thr	Ser	Ile	Pro	Ser	Gly	Gly	Asn	Ile	Gly	Tyr	Ala	Arg
	90							95						100	

Leu	Ala	Ala	Ser	Gly	Ser	Asp	Pro	Val	Ala	Gly	Ser	Ser	Ala	Thr	Val
	105					110				115					120

Ala	Gly	Trp	Gly	Ala	Thr	Ser	Glu	Gly	Gly	Ser	Ser	Thr	Pro	Val	Asn
		125						130						135	

Leu	Leu	Lys	Val	Thr	Val	Pro	Ile	Val	Ser	Arg	Ala	Thr	Cys	Arg	Ala
		140						145					150		

Gln	Tyr	Gly	Thr	Ser	Ala	Ile	Thr	Asn	Gln	Met	Phe	Cys	Ala	Gly	Val
		155						160				165			

Ser	Ser	Gly	Gly	Lys	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Ile
	170						175					180			

Val	Asp	Ser	Ser	Asn	Thr	Leu	Ile	Gly	Ala	Val	Ser	Trp	Gly	Asn	Gly
	185						190				195		200		

Cys	Ala	Arg	Pro	Asn	Tyr	Ser	Gly	Val	Tyr	Ala	Ser	Val	Gly	Ala	Leu
		205						210					215		

Arg	Ser	Phe	Ile	Asp	Thr	Tyr	Ala								
		220													

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1206 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GAATTCTTAC	AAACCTTCAA	CAGTGGAGAC	TTCGGACACG	ACATATCGAT	CCTTTGAAGA	60
TACGGTGAGC	GTCAGATCAT	GAATTTCATATA	CATCCTCACG	TCCTTCCTCT	TTCAAACATAT	120
GCAAAGTCCT	TCTAGTACCT	CCCAAAACTT	GATTTACGCG	CTCTCCAATC	AAAAGTACCT	180
TCCAAAAGTG	ATCTACCTCA	GCTCTAGATC	AGGGCACCTA	TTCGCAAAGA	TCTACAAGCT	240
GAACTAGTAA	GCATAGCGGG	AGAATATCCC	ACATCATTG	AGAAGGCCCT	CGTATTAGAC	300
CTAGTGGGAT	CGACAGAAAA	GATAAGACGG	AGATAGATGC	TATGTTGGA	AGGTAGGGGA	360
TGGAATAGGA	TGCAACAGGT	ATTGGCATAA	GCGATGCAAT	AGGTGCATCT	AGAAACTAGG	420
TGACAGACTG	GCCACAGAGG	TGTATCCTAT	GCAGGTCGAT	GCGTGCCTTA	TCGCAGGGCT	480
GCTATTCCGT	GGTGGTGGCT	ACAAAAGTTC	TATGTGGTTT	CCAGTTTCAG	AATATTGGGC	540
CATTGTGATT	GATGGCGCAT	GACCGAATTA	TAGCAGTGAA	CCCCGCCAG	AGTAGTAGTG	600
CAGATGCCCT	TTGATGCTTG	GCGATTCCCTC	GGGCTAAATA	ACTCCGGTTG	GTCTGTAGAA	660
TGCTGACGCG	ATGATCCTTC	GGCATTAATC	GTAGATCTTG	GGGGGGATA	AGCCGATCAA	720
AGACACACTG	TAGATCAGCT	CTTCGATGAC	TCTTACCAGC	TTTATAATAA	CATTACATCTT	780
GAACGTCTTT	TTCGTCCAGT	GTTCACCTTT	CGTCCTATTT	ATCCGTCTA	TCCACAGTGT	840
TATTGGCGAT	AGAGTTATCG	ACTTTCCCTCA	TCGGGATACT	GGCCCCCTGCT	GCCAAGGGCC	900
TTATATGCCG	ATCACTTTCA	CGGGAGCATG	ATAAGGTTAA	TGCTTCTTCT	GAATGCCGAA	960
CTAGACTACG	GAACAACCGGA	GCTTAGTACC	AGAAAGGCAG	GTACGCCCTAT	TCGCAAACTC	1020
CGAAGATACA	ACCAAGCAAG	CTTATCGCGG	GATAGTAACC	AGAGAGGCAG	GTAAGAAGAC	1080
ACAACAAACAT	CCATAGCTAT	GTAGATTCTC	GAATATAAAA	GGACCAAGAT	GGACTATTG	1140
AAGTAGTCTA	TCATCAACCA	CTCTCACTC	TTCAACTCTC	CTCTCTTGG	TATCTATCTC	1200
TTCACC						1206

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 1188 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TAAATACCTT	GTTGGAAGCG	TCGAGATGTT	CCTTGAATAT	TCTCTAGCTT	GAGTCTTGG	60
TACGAAACCT	GTTTGGAGAAA	TAGGTTCAA	CGAGTTAAGA	AGATATGAGT	TGATTTCACT	120
TGGATCTTAG	TCCTGGTTGC	TCGTAATAGA	GCAATCTAGA	TAGCCAAAT	TGAATATGAA	180
ATTTGATGGA	AATATTCAATT	TCGATAGAAG	CAACGTGAAA	TGTCTAGCAG	GACGAAAAGT	240

AGATCAAGGC TGTATGTT CCCGACCAAC CTACCTTGAT GTCAGTCTGC GAGTCGTGTG	300
CAGTGACCCA GAATGATGGA TTGACTTGG AATTCTGT CTATGAAGTA TTATGAACAT	360
GAATATCGTT TCCTCATTAT CTATGTTGGC AGCCTAAAGT TTTACCATAT AGCTAGCAAT	420
CAGTCAAGTA TCTGCGTATG AAGGGTTGTT AAGCCAGGAC GGTATCAGCG TTGAATATT	480
AAAGAATGAT ATGAGATAAT CAACATTGAC ATGATAAAAG AAAAGGGGAA ACAAATTGTG	540
CATATAGTAA AGACTTCAGG TCGACCCCTC AATAGACATA TGCGAACCGA AAACCAACAG	600
GATACAATTG ATAGATAAGT ATAACACAG TTATCTGTCT GCCGAACAAA TACTCTTTG	660
TGAAACAAAT GAAGAGTACA TAAGCTACAG TTCTCAGTA GGAACATCCT TTACAATAAC	720
TCCCTTGACT TCCTTCAGCT TCTCAATAGC CTCCAAAGTC ATCGGTCTGC CATCAAGGCA	780
CGTCAGCTCT GGTGTAGCAT ACAGCAGTGC CATACTTACG GAGGATAGGA AGTGGGAGGA	840
ATCGTTCGTG TCTGCCCTCA AAAATCGACA CCAGTGTCTT TTTGACGAT ACTGATATGG	900
TGGTAAGCTT GGGAGTCTAT TGTGACGTT GCATCACTTA CTTAAGCAGG GTTTCAATTCC	960
TCTGCTGATA GTCCTCCAAC TTCTCGAAGT CGTAAACGAT GGCCTATAAGT ATCTTATTGA	1020
GAAATATGTC TTCTCAGAAA ATTATATCTT GTTTACCTTT CGGTCCGCCA TGGCTGCTAA	1080
AACTGCTGGG AAATTCAAAA GCGCAGCACA AGCAGCAAGA GTGATGGGCA CAACGTGATA	1140
TGTTGATAAA AGCATCAGTA TCGATAAGTT CCACTCAGAA ACCTGCAG	1188

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1060 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 10..924

(ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 73..924

(ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 10..72

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGATCCAAG ATG CGT TCC TCC CCC CTC CTC CCG TCC GCC GTT GTG GCC	48
Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala	
-21 -20 -15 -10	
GCC CTG CCG GTG TTG GCC CTT GCT GAT GGC AGG TCC ACC CGC TAC	96
Ala Leu Pro Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr	
-5 1 5	
TGG GAC TGC TGC AAG CCT TCG TGC GGC TGG GCC AAG AAG GCT CCC GTG	144
Trp Asp Cys Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val	
10 15 20	

AAC CAG CCT GTC TTT TCC TGC AAC GCC AAC TTC CAG CGT ATC ACG GAC Asn Gln Pro Val Phe Ser Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp 25 30 35 40	192
TTC GAC GCC AAG TCC GGC TGC GAG CCG GGC GGT GTC GCC TAC TCG TGC Phe Asp Ala Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys 45 50 55	240
GCC GAC CAG ACC CCA TGG GCT GTG AAC GAC GAC TTC GCG CTC GGT TTT Ala Asp Gln Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe 60 65 70	288
GCT GCC ACC TCT ATT GCC GGC AGC AAT GAG GCG GGC TGG TGC TGC GCC Ala Ala Thr Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala 75 80 85	336
TGC TAC GAG CTC ACC TTC ACA TCC GGT CCT GTC GGC AAG AAG ATG Cys Tyr Glu Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met 90 95 100	384
GTC GTC CAG TCC ACC AGC ACT GGC GGT GAT CTT GGC AGC AAC CAC TTC Val Val Gln Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe 105 110 115 120	432
GAT CTC AAC ATC CCC GGC GGC GTC GGC ATC TTC GAC GGA TGC ACT Asp Leu Asn Ile Pro Gly Gly Val Gly Ile Phe Asp Gly Cys Thr 125 130 135	480
CCC CAG TTC GGC GGT CTG CCC GGC CAG CGC TAC GGC GGC ATC TCG TCC Pro Gln Phe Gly Gly Leu Pro Gly Gln Arg Tyr Gly Ile Ser Ser 140 145 150	528
CGC AAC GAG TGC GAT CGG TTC CCC GAC GCC CTC AAG CCC GGC TGC TAC Arg Asn Glu Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr 155 160 165	576
TGG CGC TTC GAC TGG TTC AAG AAC GGC GAC AAT CCG AGC TTC AGC TTC Trp Arg Phe Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe 170 175 180	624
CGT CAG GTC CAG TGC CCA GCC GAG CTC GTC GCT CGC ACC GGA TGC CGC Arg Gln Val Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg 185 190 195 200	672
CGC AAC GAC GAC GGC AAC TTC CCT GCC GTC CAG ATC CCC TCC AGC AGC Arg Asn Asp Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser 205 210 215	720
ACC AGC TCT CCG GTC AAC CAG CCT ACC AGC ACC AGC ACC ACG TCC ACC Thr Ser Ser Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Ser Thr 220 225 230	768
TCC ACC ACC TCG AGC CCG CCA GTC CAG CCT ACG ACT CCC AGC GGC TGC Ser Thr Thr Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys 235 240 245	816
ACT GCT GAG AGG TGG GCT CAG TGC GGC GGC AAT GGC TGG AGC GGC TGC Thr Ala Glu Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys 250 255 260	864
ACC ACC TGC GTC GCT GGC AGC ACT TGC ACG AAG ATT AAT GAC TGG TAC Thr Thr Cys Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr 265 270 275 280	912
CAT CAG TGC CTG TAGACGCAGG GCAGCTTGAG GGCCCTTACTG GTGGCCCGCAA His Gln Cys Leu	964

CGAAATGACA CTCCAATCA CTGTATTAGT TCTTGTACAT AATTCGTCA TCCCTCCAGG 1024
 GATTGTCACA TAAATGCAAT GAGGAACAAT GAGTAC 1060

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 305 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Arg Ser Ser Pro Leu Leu Pro Ser Ala Val Val Ala Ala Leu Pro
 -21 -20 -15 -10

Val Leu Ala Leu Ala Ala Asp Gly Arg Ser Thr Arg Tyr Trp Asp Cys
 -5 1 5 10

Cys Lys Pro Ser Cys Gly Trp Ala Lys Lys Ala Pro Val Asn Gln Pro
 15 20 25

Val Phe Ser Cys Asn Ala Asn Phe Gln Arg Ile Thr Asp Phe Asp Ala
 30 35 40

Lys Ser Gly Cys Glu Pro Gly Gly Val Ala Tyr Ser Cys Ala Asp Gln
 45 50 55

Thr Pro Trp Ala Val Asn Asp Asp Phe Ala Leu Gly Phe Ala Ala Thr
 60 65 70 75

Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Ala Cys Tyr Glu
 80 85 90

Leu Thr Phe Thr Ser Gly Pro Val Ala Gly Lys Lys Met Val Val Gln
 95 100 105

Ser Thr Ser Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Asn
 110 115 120

Ile Pro Gly Gly Val Gly Ile Phe Asp Gly Cys Thr Pro Gln Phe
 125 130 135

Gly Gly Leu Pro Gly Gln Arg Tyr Gly Gly Ile Ser Ser Arg Asn Glu
 140 145 150 155

Cys Asp Arg Phe Pro Asp Ala Leu Lys Pro Gly Cys Tyr Trp Arg Phe
 160 165 170

Asp Trp Phe Lys Asn Ala Asp Asn Pro Ser Phe Ser Phe Arg Gln Val
 175 180 185

Gln Cys Pro Ala Glu Leu Val Ala Arg Thr Gly Cys Arg Arg Asn Asp
 190 195 200

Asp Gly Asn Phe Pro Ala Val Gln Ile Pro Ser Ser Ser Thr Ser Ser
 205 210 215

Pro Val Asn Gln Pro Thr Ser Thr Ser Thr Ser Thr Ser Thr Thr
 220 225 230 235

Ser Ser Pro Pro Val Gln Pro Thr Thr Pro Ser Gly Cys Thr Ala Glu
 240 245 250

Arg Trp Ala Gln Cys Gly Gly Asn Gly Trp Ser Gly Cys Thr Thr Cys
255 260 265

Val Ala Gly Ser Thr Cys Thr Lys Ile Asn Asp Trp Tyr His Gln Cys
270 275 280

Leu

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 876 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAGGAGCT	CCCTTGTGCT	TTCTTGTC	TCTGCGTGGA	CGGCCTTGCC	CAGTCCTATT	60
CGTCGAGAGG	TCTCGCAGGA	TCTGTTAAC	CAGTTCAATC	TCTTGCACA	GTATTCTGCA	120
GCCGCATACT	GCGGAAAAAA	CAATGATGCC	CCAGCTGGTA	CAAACATTAC	GTGCACGGGA	180
AATGCCTGCC	CCGAGGTAGA	GAAGGCGGAT	GCAACGTTTC	TCTACTCGTT	TGAAGACTCT	240
GGAGTGGCG	ATGTCACCCG	CTTCCTTGCT	CTCGACAACA	CGAACAAATT	GATCGTCCTC	300
TCTTTCCGTG	GCTCTCGTTC	CATAGAGAAC	TGGATCGGGA	ATCTTAACCTT	CGACTTGAAA	360
GAAATAATG	ACATTTGCTC	CGGCTGCAGG	GGACATGACG	GCTTCACTTC	GTCCTGGAGG	420
TCTGTAGCCG	ATACGTTAAG	GCAGAAGGTG	GAGGATGCTG	TGAGGGAGCA	TCCCGACTAT	480
CCCGTGGTGT	TTACCGGACA	TAGCTTGGGT	GGTGCATTGG	CAACTGTTGC	CGGAGCAGAC	540
CTGCGTGGAA	ATGGGTATGA	TATCGACGTG	TTTCATATG	GCGCCCCCCC	AGTCGGAAAC	600
ACGGCTTTTG	CAGAATT CCT	GACCGTACAG	ACCGGCGGAA	CACTCTACCG	CATTACCCAC	660
ACCAATGATA	TTGTCCCTAG	ACTCCGCCG	CGCGAATT CG	GTTACAGCCA	TTCTAGCCCA	720
GAGTACTGGA	TCAAATCTGG	AACCCTGTC	CCCGTCACCC	GAAACGATAT	CGTGAAGATA	780
GAAGGCATCG	ATGCCACCGG	CGGCAATAAC	CAGCCTAAC	TTCCGGATAT	CCCTGCGCAC	840
CTATGGTACT	TCGGGTTAAT	TGGGACATGT	CTTTAG			876

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 291 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu
1 5 10 15

Ala Ser Pro Ile Arg Arg Glu Val Ser Gln Asp Leu Phe Asn Gln Phe
20 25 30

Asn Leu Phe Ala Gln Tyr Ser Ala Ala Ala Tyr Cys Gly Lys Asn Asn

35	40	45
Asp Ala Pro Ala Gly Thr Asn Ile Thr Cys Thr Gly Asn Ala Cys Pro		
50	55	60
Glu Val Glu Lys Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu Asp Ser		
65	70	75
80		
Gly Val Gly Asp Val Thr Gly Phe Leu Ala Leu Asp Asn Thr Asn Lys		
85	90	95
Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Ile Glu Asn Trp Ile		
100	105	110
Gly Asn Leu Asn Phe Asp Leu Lys Glu Ile Asn Asp Ile Cys Ser Gly		
115	120	125
Cys Arg Gly His Asp Gly Phe Thr Ser Ser Trp Arg Ser Val Ala Asp		
130	135	140
Thr Leu Arg Gln Lys Val Glu Asp Ala Val Arg Glu His Pro Asp Tyr		
145	150	155
160		
Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Val		
165	170	175
Ala Gly Ala Asp Leu Arg Gly Asn Gly Tyr Asp Ile Asp Val Phe Ser		
180	185	190
Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr		
195	200	205
Val Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile		
210	215	220
Val Pro Arg Leu Pro Pro Arg Glu Phe Gly Tyr Ser His Ser Ser Pro		
225	230	240
235		
Glu Tyr Trp Ile Lys Ser Gly Thr Leu Val Pro Val Thr Arg Asn Asp		
245	250	255
Ile Val Lys Ile Glu Gly Ile Asp Ala Thr Gly Gly Asn Asn Gln Pro		
260	265	270
Asn Ile Pro Asp Ile Pro Ala His Leu Trp Tyr Phe Gly Leu Ile Gly		
275	280	285
Thr Cys Leu		
290		

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCACACCATG GTCGCTGGAT CCATACCTTG TTGGAAGCGT CG

42

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATCGGAGCAT GCGGTACCGT TTAAACGAAT TCAGGTAAAC AAGATATAAT TTTCTG

56

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTCTTGGATA TCTATCTCTT CACCATGGGT TCCTCCCCCC TCCT

44

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAATAGAGGT GGCAGCAAAA

20

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATCTATCTCT TCACCATGAG GAGCT

25

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TAGATAGAGA AGTGGTACTC C

21

What is claimed is:

1. A non-toxic, non-toxigenic, non-pathogenic recombinant *Fusarium* host cell comprising a nucleic acid sequence encoding a heterologous protein operably linked to a promoter.

5

2. The host cell of claim 1 in which the *Fusarium* is *Fusarium graminearum*.

10

3. The host cell of claim 1 in which the *Fusarium graminearum* has the identifying characteristics of ATCC 20334.

15 4. The host cell of claim 1 in which the heterologous protein is a fungal protein.

5. The host cell of claim 1 in which the heterologous protein is a secreted protein.

20 6. The host cell of claim 1 in which the heterologous protein is a fungal enzyme.

25

7. The host cell of claim 6 in which the fungal enzyme is selected from the group consisting of a catalase, laccase, phenoloxidase, oxidase, oxidoreductases, cellulase, xylanase, peroxidase, lipase, hydrolase, esterase, cutinase, a proteolytic enzyme, aminopeptidase, carboxypeptidase, phytase, lyase, a pectinolytic enzymes, amylase, glucoamylase, α -galactosidase, β -galactosidase, α -glucosidase, β -glucosidase, mannosidase, isomerase, invertase, transferase, ribonuclease, chitinase, and deoxyribonuclease.

30

8. The host cell of claim 6 in which the fungal enzyme is a protease.

9. The host cell of claim 6 in which the fungal enzyme is an alkaline protease.

35 10. The host cell of claim 9 in which the alkaline protease is a *Fusarium oxysporum* trypsin-like protease.

11. The host cell of claim 10 in which the *Fusarium oxysporum* trypsin-like

protease has an amino sequence shown in SEQ ID NO:4.

12. The host cell of claim 6 in which the fungal enzyme is an endoglucanase or variant thereof.

5

13. The host cell of claim 14 in which the endoglucanase has an amino acid sequence shown in SEQ ID NO:8.

10 14. The host cell of claim 6 in which the fungal enzyme is a 1,3 lipase or variant thereof.

15 15. The host cell of claim 12 in which the 1,3 lipase has an amino acid sequence shown in SEQ ID NO:10.

16. The host cell of claim 1 in which the heterologous protein is selected from the group consisting of a hormone, a growth factor and a receptor.

20 17. The host cell of claim 1 in which the promoter is a fungal promoter.

18. The host cell of claim 17 in which the promoter is selected from the group consisting of the promoters from *A. nidulans* *amdS*.

25 19. The host cell of claim 17 in which said fungal promoter is derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same promoter activity as said sequence.

20. The host cell of claim 19 in which said promoter sequence is shown in SEQ ID NO:5.

30 21. The host cell of claim 1 which also comprises a selectable marker.

22. The host cell of claim 13 in which the marker is selected from the group consisting of *argB*, *trpC*, *pyrG*, *amdS*, *niaD* and *hygB*.

35 23. The host cell of claim 1 which also comprises a terminator.

24. The host cell of claim 23 in which said terminator is derived from a gene

encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same terminator activity as said sequence.

25. The host cell of claim 24 in which said terminator sequence is shown in
5 SEQ ID NO:6.

26. A method for producing a protein of interest which comprises culturing a non-toxic, non-toxigenic, non-pathogenic recombinant *Fusarium* host cell comprising a nucleic acid sequence encoding a said protein operably linked to a promoter and isolating said protein.

10

27. A promoter sequence derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same promoter activity as said sequence in which said promoter has the sequence shown in SEQ ID NO:5.

15

28. A terminator sequence derived from a gene encoding a *Fusarium oxysporum* trypsin-like protease or a fragment thereof having substantially the same terminator activity as said sequence in which said terminator has the sequence shown in SEQ ID NO:6.




FIG.1




FIG. 2

F. OXYSPORUM DNA




SUBCLONING OF PstI
FRAGMENT INTO pUC118SUBCLONING OF EcoRI
FRAGMENT INTO pToC90

FIG.3
3/14
SUBSTITUTE SHEET (RULE 26)






FIG. 4

4/14

**FIG.5****FIG.6**




FIG.7




FIG.8A




FIG. 8B




FIG. 9A






FIG.9B

10/14

SUBSTITUTE SHEET (RULE 26)






FIG. 12




FIG.13




FIG. 14

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/07743

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/80 C12N5/10 C12P21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROTEIN ENG., vol. 6, 1993 pages 341-348, W.R. RYPNIEWSKI ET AL.; 'The sequence and X-ray structure of the trypsin from <i>Fusarium oxysporum</i> ' see abstract and Figure 2. ---	27,28
Y	CURR. GENET., vol. 15, 1989 pages 453-456, M.J. DABOSSI ET AL.; 'Transformation of seven species of filamentous fungi using the nitrate reductase gene of <i>Aspergillus nidulans</i> ' see the whole document. ---	1-26 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *& document member of the same patent family

Date of the actual completion of the international search

2 October 1995

Date of mailing of the international search report

03. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Yeats, S

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 95/07743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MYCOL. RES., vol. 97, 1992 pages 313-317, H.J. CURRAGH ET AL.; 'Protoplast formation and DNA-mediated transformation of <i>Fusarium culmorum</i> to hygromycin B resistance' cited in the application see the whole document. ---	1-26
Y	CURR. GENET., vol. 21, 1992 pages 463-469, R.N. CROWHURST ET AL.; 'High efficiency transformation of <i>Fusarium solani</i> f. sp. <i>cucurbitae</i> race 2 (mating population V)' cited in the application see abstract. ---	1-26
Y	MOLEC. GEN. GENET., vol. 236, 1992 pages 121-124, C.T. YAMASHIRO ET AL.; 'A dominant selectable marker that is meiotically stable in <i>Neurospora crassa</i> : the <i>amdS</i> gene of <i>Aspergillus nidulans</i> ' see the whole document. -----	22